Search
Incyte Corp
INCYAdd to Watchlist
114.660USD
+0.910+0.80%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
22.93BMarket Cap
15.71P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.80%
5 Days
+10.61%
1 Month
+18.52%
6 Months
+15.48%
Year to Date
+16.09%
1 Year
+67.71%
Key Figures
114.800Open
115.480High
1.53MVolume
15.71P/E TTM
12.15P/E Dynamic
--Dividend TTM
0.77%Turnover Ratio
113.750Prev. Close
112.890Low
145.23MTurnover
702.93P/E Static
4.08P/B
0.00%Div Yield TTM
21.88%ROA
112.29052wk High
0.67Volume Ratio
32.62MNet Profit
199.95MShares
7.2963EPS TTM
0.79Beta
30.82%ROE
63.92552wk Low
2.28%Amplitude
91.79%Gross Margin
22.93BMarket Cap
9.62Reward/Risk
1.83%Risk Rate
TradingKey Stock Score of Incyte Corp
Currency: USD Updated: 2026-06-29Key Insights
Incyte Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 111.62.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Incyte Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Incyte Corp Highlights
StrengthsRisks
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.12% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.14B.
Undervalued
The company’s latest PE is 15.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 209.33M shares, decreasing 1.76% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 30.41K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
111.624
Target Price
-1.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Incyte Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Incyte Corp Info
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Ticker SymbolINCY
CompanyIncyte Corp
CEOMeury (Bill)
Websitehttps://www.incyte.com/
Related Instruments
+1.74%
+1.48%
+1.38%
+0.30%
+0.56%
+1.38%
+0.62%
+0.56%
-1.21%
+0.39%
+1.69%
+1.79%
+0.59%
+1.12%
-2.09%
0.00%
-0.17%
+2.85%
-0.74%
+0.47%Popular Instruments
FAQs
What is the current price of Incyte Corp (INCY)?
The current price of Incyte Corp (INCY) is 114.66.
What is the symbol of Incyte Corp?
The ticker symbol of Incyte Corp is INCY.
What is the 52-week high of Incyte Corp?
The 52-week high of Incyte Corp is 112.29.
What is the 52-week low of Incyte Corp?
The 52-week low of Incyte Corp is 63.92.
What is the market capitalization of Incyte Corp?
The market capitalization of Incyte Corp is 22.93B.
Is Incyte Corp (INCY) currently rated as Buy, Hold, or Sell?
According to analysts, Incyte Corp (INCY) has an overall rating of Buy, with a price target of 111.62.
What is the Earnings Per Share (EPS TTM) of Incyte Corp (INCY)?
The Earnings Per Share (EPS TTM) of Incyte Corp (INCY) is 6.59.
